Skip Navigation Links   >   Home   >   News & Media
09 August 2018

High life: the start-up hoping to unlock the secrets of medical cannabis

Medical cannabis has been all the rage in the UK of late. 

Headlines about two young epilepsy sufferers, Billy Caldwell and Alfie Dingely, who were denied access to cannabis oil that helped keep their conditions under control, sparked a debate that led to the home secretary Sajid Javid's decision to allow medical cannabis to be available on prescription in the UK.  

Whilst the wonders of cannabis have been touted for conditions such as cancer and arthritis, relatively little is known about the green leaf and its supposedly magical properties. 

That’s where Oxford Cannabinoid Technologies (OCT) comes in. The bio-tech start-up, founded by Kingsley Capital Partners, has been launched in partnership with the University of Oxford to research the potential benefits of the plant. 

OCT’s chairman, and managing partner at Kingsley, Neil Mahapatra, became interested in the medical cannabis market after seeing the growth in the UK following its legalisation there.

However, it wasn’t until he lost his mother to lung cancer, that he began to really research the impact cannabis could have on diseases. 

“Whilst there is something to suggest cannabis can help with cancer, nowhere near enough research is being done,” he tells the Standard. “Yet, in the regions where cannabis is legal, it is under the guise of having medical benefits.”

Mahapatra, who studied his undergraduate degree in Biology at the University of Oxford, decided to turn to his old biology professor to discuss it. “I said: ‘The medical cannabis market is opening up, no one understands how it works, why don’t we design a research programme with Oxford?” 

With that, OCT was born.

Read the full article here

    All News

    • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

      06 July 2021 Partnership
    • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      24 June 2021 iCDP Speaker
    • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      22 June 2021 Meet the Team Interview Series
    • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

      04 June 2021 Live Presentation
    • OCT Forges Partnership with Voisin Consulting Life Sciences

      OCT Forges Partnership with Voisin Consulting Life Sciences

      01 June 2021 OCT Partnership
    • Oxford Cannabinoid Technologies Announces Changes to Executive Team

      11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
    • OCT Company Values: How We Pursue Our Mission and Vision

      OCT Company Values: How We Pursue Our Mission and Vision

      01 December 2020 OCT Company Values
    • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

      Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

      26 October 2020 Meet the Team Interview Series
    • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

      07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
    • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

      OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

      28 July 2020 OCT Press Release
    • Cannabinoids in medicine part 5: Treating COVID-19

      17 June 2020 Open Access Government
    • Why the Government should continue to invest in Life Sciences post COVID-19

      Why the government should continue to invest in Life Sciences post COVID-19

      01 June 2020 OCT blog - John Lucas, COO
    • OCT researchers publish new study examining genes involved in treating neuropathic pain

      19 April 2020 OCT Press Release
    • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

      03 April 2020 OCT Press Release
    • Cannabinoids in medicine part 4: Epilepsy

      30 March 2020 Open Access Government
    • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

      07 January 2020 Open Access Government
    • Cannabinoids in medicine Part 2: Pain

      11 October 2019 Open Access Government
    • Cannabinoids in medicine Part 1: Cancer

      22 August 2019 Open Access Government
    • An interview with Neil Mahapatra

      08 January 2019 The Times Magazine
    • High life: the start-up hoping to unlock the secrets of medical cannabis

      09 August 2018 Evening Standard
    • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

      28 June 2018 OCT Press Release
    • Embracing the medical potential of cannabinoids

      01 June 2017 The Medicine Maker
    • Smashing the stigma with science

      01 June 2017 The Medicine Maker
    • Oxford University launches £10m research project into medical marijuana

      16 March 2017 Evening Standard
    • Oxford University to launch study on medical benefits of marijuana

      16 March 2017 The Telegraph
    • Oxford University to launch multimillion-dollar medical marijuana research program

      16 March 2017 CNBC
    • Oxford University launches £10m marijuana research programme

      16 March 2017 BBC
    • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

      15 March 2017 OCT Press Release